Inside Finnrick: Peptide Testing, Paywalls, Privacy and the Problem With Overfill

CEO Raphaël Mazoyer answers questions about disputed results, laboratory selection, vendor payments, data security and what Finnrick believes the grey market is getting wrong

K-Hole Interview | London; 18 September 2026

Finnrick occupies an unusual and increasingly powerful position in the grey peptide market, the informal market for products sold as research peptides outside conventional pharmaceutical supply chains. It doesn’t manufacture peptides and it doesn’t run the labs that analyse them. Instead, it sits between buyers, vendors and independent laboratories, receiving samples, arranging tests, deciding which results qualify for publication and converting those results into public vendor ratings.

That makes Finnrick useful, but it also raises difficult questions. Who decides which laboratories can be trusted? What happens when a result is challenged? Can a vendor pay to establish a listing and suppress an unfavourable launch result? Why are original COAs now behind a membership fee? How much information does Finnrick hold about the people and companies using the service, and what would happen if a regulator demanded it?

While Mazoyer was visiting London, I met him for coffee and put those questions to him during a wide-ranging, in-person recorded interview. He defended the company’s stance on overfilling, explained why some test results are not published, acknowledged that Finnrick may have relied too heavily on one laboratory and agreed to review a specific disputed result involving Uther and Krause Analytical.

He also described a market in which the familiar problems of low purity and inaccurate filling may no longer be the only concerns. Finnrick is now seeing vials with no active peptide, severe underdosing and substances that its current routine testing cannot fully explain.

Editorial note: This article is based on a recorded interview. Quotations have been lightly edited for clarity without changing their meaning and Raphael has checked this prior to publishing. Links to Finnrick’s public pages have been added to verify current programme names, laboratory names and published figures.

From a privacy-first project to more than 10,000 published tests

Mazoyer said work on Finnrick began in October 2024. Its original design was influenced heavily by the established peptide community, where anonymity and caution were treated as essential rather than optional.

“Everything I know about peptides I learned from that community,” he said. Early technical decisions were made with its concerns in mind: minimal tracking, limited personal information and a deliberate effort to avoid giving privacy-conscious users a reason to distrust the platform.

He believes the audience has since changed. A much larger group of people has entered the peptide market, many of whom appear far less concerned about protecting their identities. That didn’t lead him to dismiss the caution of the original community. If anything, he said two years inside the market had made him more sympathetic to it.

Why he no longer dismisses the community’s suspicion

Mazoyer said two years inside the market had made him more sympathetic to the original community’s distrust. He cited the Friday-evening timing of an announcement by Robert F. Kennedy Jr. about proposed changes affecting the peptide market and Chinese supply routes, which he interpreted as an example of political tactics taking precedence over the people affected. In his view, the response exposed tension between Republican trade hawks concerned about Chinese precursor routes and more libertarian or MAHA-aligned figures who favoured broader access.

This was Mazoyer’s interpretation of the episode rather than a finding by Finnrick, but it led him to conclude that the older community’s caution had not been entirely misplaced. “The core peptide community that we started with were probably onto something in terms of how cautious and suspicious they can be,” he said. He remains sceptical of claims that Finnrick secretly works for the FDA, pharmaceutical companies or the Chinese government; his narrower point was that institutional incentives are not always aligned with the people affected by a policy.

A contemporaneous check of Finnrick’s public homepage on 15 September 2026 showed 10,399 tests, including 3,856 retatrutide tests. During the interview, Mazoyer said the company had processed roughly 18,000 tests in total, with the difference including private results and tests that didn’t meet Finnrick’s publication requirements.

That volume is central to Mazoyer’s defence of the company. Finnrick isn’t a laboratory and he doesn’t present himself as an analytical chemist. Its claimed advantage is the ability to compare large numbers of results across laboratories, products, vendors and purported batches.

“Volume is what gives us our authority,” he said. More precisely, volume gives Finnrick the ability to identify patterns. Whether those patterns are always interpreted correctly is a separate question.

“New modes of failure”

Retatrutide, an investigational drug currently undergoing human clinical trials and not approved for general clinical use, is, by a large margin, the most frequently submitted product. The scale of those submissions has shown Finnrick problems that Mazoyer says were uncommon or less visible when the service started.

Finnrick’s analysis of approximately 21,275 testing requests submitted between February 2025 and May 2026 provides more detail about that demand. According to the company, GLP-1 products accounted for 63% of requests, with retatrutide and cagrilintide together representing 38%. Finnrick classified 66% of all requests as involving products without FDA approval. Quarterly requests increased from approximately 1,900 in the second quarter of 2025 to more than 7,100 in the first quarter of 2026.

These figures describe requests submitted through Finnrick rather than completed tests or the wider grey peptide market. Mazoyer said the numbers could be updated, although he didn’t expect the underlying trends to have changed.

The market has previously experienced waves of “zero peptide” results, where no claimed active ingredient could be detected. According to Mazoyer, those cases are appearing again alongside severe underfilling and material that doesn’t resemble an acceptable injectable formulation.

“We are seeing new modes of failure that we weren’t seeing before,” he said. The concern is no longer limited to whether a vial contains the correct peptide at the expected purity and quantity. Finnrick is now asking what else may be present. Mazoyer said the company had previously assumed that an identity failure might simply leave an inert excipient such as mannitol. He now considers that assumption unsafe.

He’s working with Dr Ducor and several partner laboratories to examine which additional tests could be offered at a realistic price. A comprehensive investigation can cost thousands of dollars per vial, which isn’t workable for routine community testing. The aim is to find an affordable screening pathway that can answer two separate questions: does the vial contain the claimed peptide, and is there anything else present that should not be injected?

Mazoyer said unfamiliar buffers and other unexpected material may not be detected adequately by the routine purity, identity and quantity package. Sterility testing is another area he wants Finnrick to expand, provided faster and more affordable methods can be offered. His broader suspicion is that some suppliers with experience in cosmetics may be moving into injectable products without equivalent manufacturing controls. He was clear, however, that this remains a working theory rather than a conclusion established by Finnrick’s data.

Is purity still the right headline number?

Mazoyer also questioned whether the market’s long-standing focus on purity is still serving buyers well. He described it as a legacy of the bodybuilding and underground-steroid communities: a simple number that has been used for decades because it’s easy to understand and was often the best information available. His personal view is that a correctly identified peptide above 98% purity is generally acceptable. Finnrick nevertheless released a website update that places considerable emphasis on stricter purity thresholds because that’s what many users want to compare. “I do not necessarily vouch for that, but we’ve got the data,” he said.

The larger problem is that a high purity result doesn’t establish accurate quantity, acceptable endotoxin levels, sterility or the absence of an unsuitable buffer. A vial may look good under the headline purity number, while leaving other important questions unanswered.

Mazoyer said Finnrick had generated enough endotoxin-testing volume to see what he described as a “non-negligible” number of concerning results. Some contained only traces that might be explained by the environment; others reached levels he regarded as a genuine risk. He didn’t provide a percentage during the interview, so the size of that problem can’t yet be quantified from his comments alone.

Heavy-metal testing presents the opposite problem. It costs hundreds of dollars, demand is limited and Finnrick hasn’t accumulated enough results to determine whether contamination is common. Mazoyer said the company is no longer actively selling that test. Sterility is his next intended area of expansion, provided Finnrick can obtain a faster method at a price customers will actually pay.

This creates a difficult commercial loop. Finnrick needs volume to learn whether a hazard is common, but it needs buyers to pay for the testing before that volume exists. It must persuade people that a test is worth buying before it has enough data to show how often the test finds anything.

Overfill: no apology and no change of principle

Finnrick’s treatment of overfilled vials has been controversial from the beginning. In the grey market, buyers often regard receiving 12 mg in a vial sold as 10 mg as a bonus. Some vendors deliberately overfill, partly to protect against analytical variation or loss during handling. Mazoyer remains unconvinced. He doesn’t regard substantial overfill as generosity; he sees it as potential evidence that the vendor doesn’t control its filling operation or supply chain.

“These aren’t potatoes,” he said. “You need to know what it is that you’re putting in the vials.”

He therefore does not regret Finnrick penalising vendors for inaccurate filling. His position is that dosing accuracy should mean accuracy in both directions. A vial containing considerably more than the label claim may expose a user to a larger dose than intended, even if the buyer believes they received better value.

Finnrick’s current system does, however, allow users to view the data under different standards. Its recently introduced “Accuracy Focus” allows purity down to 98% but requires quantity to fall within ±20% of the label claim and can incorporate endotoxin results. Other modes place more emphasis on very high purity. Finnrick explains the current options in its September laboratory update.

Mazoyer’s next step is to test whether inaccurate filling correlates with other quality failures. He believes uncontrolled quantity, poor manufacturing practices and additional contamination risks may share the same underlying cause, but he doesn’t yet claim to have proved that relationship. The dispute helped put Finnrick on the map after Jay Campbell publicly challenged the company’s treatment of overfilled products. Mazoyer remains unmoved by the argument that a customer who pays for 10 mg and receives 12 mg has simply received a better deal. In his view, the extra 2 mg may reveal that neither the vendor nor its supplier has a reliable grip on the filling process.

If the testing is free, why is Finnrick charging?

Finnrick began with free community testing at the centre of its identity. It now also sells private testing, laboratory selection, memberships, vendor reports, alerts and access to original COAs. That has led to accusations that a community service has become a fee-based platform. Mazoyer’s answer is sustainability. He said the company initially relied on investment, but a testing service that depends indefinitely on outside funding could disappear as soon as investors lose interest. Paid products are intended to support the free programme and give Finnrick a realistic chance of still existing in five or ten years. He estimated that free tests currently account for somewhere between one-third and one-half of Finnrick’s total volume, depending on operational pressure and available capacity. Finnrick’s public homepage currently advertises free community testing alongside paid standard and custom services.

At the time of writing, Finnrick’s membership page advertised access to original laboratory PDFs for $9.99 per month. Mazoyer said the extracted results remain publicly visible on individual result pages: identity, purity, quantity and Finnrick’s assessment can still be read without paying. The paywall covers the original COA and additional features rather than the basic test data.

“I am adamant that the data points need to still be available to everyone,” he said.

He acknowledged that the exact balance remains under review. Finnrick is also developing an MCP service that would allow AI systems to query its testing database. Mazoyer said access to that tool may carry a fee because the infrastructure and convenience have commercial value, even if the underlying public data remains available. The distinction is important. Finnrick isn’t simply charging people to see whether a particular vial passed or failed, it’s increasingly charging for the evidence file, more advanced analysis, automated access and convenience built around information produced through a mixture of community samples, vendor submissions and paid tests.

The vendor programme and the pay-to-play question

The most sensitive part of Finnrick’s commercial model is Launch with Finnrick, a programme allowing vendors to establish a verified listing. Mazoyer said participating vendors pay what he described as a modest fee, barely exceeding the testing costs, and submit four samples. Finnrick chooses two for testing and retains the other two for possible cross-testing, internal research or comparison with samples later submitted by the public.

The vendor is shown the findings and may either authorise or reject publication, but can’t alter the results. If publication is rejected, the results remain private, the order is terminated and the vendor may place another order later. Published results carry a clear marker identifying them as part of the Launch programme and don’t contribute to Finnrick’s vendor ratings. Each vendor is limited to one Launch-generated set of two results per product; any additional results must come from public submissions or purchases made by Finnrick.

Finnrick’s published sample-provenance policy states that vendor launch submissions are treated as verified at receipt, while ordinary public submissions require independent corroboration. This is the part of the model that needs the clearest explanation. Finnrick says it doesn’t remove published results merely because a vendor objects, but an unfavourable launch result can be withheld before publication. Both statements can be true, yet consumers need to understand the distinction.

Why Finnrick does not publish every community result

According to Mazoyer, the restriction on publication isn’t limited to whether a vendor pays. It’s primarily about provenance: can Finnrick establish that a sample really came from the named seller?

Finnrick may already have purchased from the vendor, allowing it to compare packaging, order channels and proof of purchase. It may have several independent submissions that corroborate one another. Alternatively, a vendor may have established the product through the launch programme. If Finnrick receives a single unlabelled vial accompanied only by an unknown person’s claim that it came from a named competitor, Mazoyer doesn’t consider that sufficient for public attribution. The submitter can still receive the result privately, but the named vendor may not appear in the public database. This approach is designed partly to prevent hostile submissions. A vendor or supporter could otherwise submit its own bad vial while falsely naming a competitor. Finnrick now requests more batch information and proof of purchase and rejects more applications than it did previously.

The system isn’t foolproof. A legitimate vendor can source different batches from different factories, recycle batch codes or choose cap colours that match an existing COA. Mazoyer acknowledged that cap colour, trim colour and batch ID are only individual pieces of a larger assessment. Finnrick is considering a more formal vendor inspection service modelled loosely on established supply-chain audits. That could give better vendors an opportunity to demonstrate how they source and control their products, but it remains a future proposal rather than an existing safeguard.

Mazoyer also described increasingly polished websites that impersonate or appropriate the names of Chinese laboratories and manufacturers. Some of the underlying companies have little reason to maintain a Western retail website or police use of their brands, leaving space for unrelated sellers to build convincing storefronts. He said Finnrick had heard from customers who paid hundreds of dollars to such sites and received nothing.

Who qualifies for free testing?

Free testing is reserved for individual buyers, but the line between an enthusiastic customer, a group-buy organiser and a vendor is not always obvious. Mazoyer admitted that Finnrick’s decision can involve a subjective judgement.

The order form applies some automatic restrictions. Multiple samples of the same product are more likely to be rejected because Finnrick has found that pattern to be associated with vendors presenting themselves as ordinary customers. A submission containing several different GLP-1 products may also prompt questions about whether it represents one person’s genuine use.

Proof of purchase and complete product information make approval more likely. After that, a Finnrick employee reviews the order and decides whether it “feels like a vendor.” Mazoyer acknowledged that the threshold is “a little bit arbitrary,” but said demand exceeds the number of free tests Finnrick can fund, allowing the company to be selective.

The check is imperfect in both directions. Legitimate individuals may be treated with suspicion, while some vendors get through and later use the resulting COAs as marketing material. Mazoyer said Finnrick often discovers the commercial connection only when people begin asking the company to verify a certificate.

Pressure, attempted influence and legal threats

I asked Mazoyer whether anyone had ever tried to bribe Finnrick. His immediate answer was yes, although he then said “bribe” might be too strong a word for most of what had occurred. He described commercial counterparties suggesting that they would stop paying for services or subscriptions while unfavourable results remained online. Others had offered free samples in circumstances where the expected benefit was left vague. Nobody had arrived with a suitcase of money, he joked, but he had encountered an expectation that future business should lead Finnrick to change or soften a result.

Mazoyer said Finnrick doesn’t operate on that basis. The company has also begun receiving formal cease-and-desist letters, particularly from US distributors disputing whether a tested sample was genuinely theirs. He said lawyers were unnecessary because Finnrick already has a claims process: provide evidence and the company will review it. Some challenges have been resolved in the vendor’s favour and have resulted in corrections. Others have been rejected because the evidence didn’t support changing the record. Mazoyer also described people apparently impersonating legitimate vendors in an attempt to use the complaints process, including one case in which the claimant’s domain had been registered only weeks earlier.

He made an important admission about the limits of the system: publishing more information inevitably means that some published details will be wrong. Finnrick can’t conclusively adjudicate every conflicting claim, so it applies rules it believes it can defend and corrects the record when stronger evidence emerges.

The disputed Uther/Krause result

I raised one specific case involving a Uther product tested through Finnrick by Krause Analytical. Other vials presented as belonging to the same batch produced compatible results at other laboratories, while the Krause result said the submitted sample wasn’t the claimed peptide. The customer maintained that Krause had made a mistake, but the Finnrick result remained online. Mazoyer didn’t accept during the interview that the Krause result had been disproved. He asked for the exact Finnrick record ID and said the case required a specific review rather than a generic answer. He described three possible points of failure.

Krause could have analysed or interpreted its data incorrectly;

Finnrick could have mislabeled or mixed up a sample during handling;

or the vial tested by Krause could genuinely have differed from the other vials despite carrying the same supposed batch information.

Mazoyer committed to checking Finnrick’s chain-of-custody records. If Finnrick or the lab made a demonstrable mistake, he said a correction would be issued. If no evidence of an error is found, Finnrick will continue to stand by the published result. That means the case remains unresolved. Other vials producing different findings don’t, by themselves, prove that Krause tested the same contents incorrectly. Equally, the continued presence of the original result isn’t proof that Finnrick’s chain of custody and Krause’s interpretation were correct. The promised review is the part that can settle whether a correction is warranted or not.

Why does Krause conduct so much of Finnrick’s testing?

Krause has received more community criticism than Finnrick’s other partner laboratories, particularly over results that diverged from other tests. Mazoyer rejected the broad claim that Krause is simply an unreliable laboratory.

At the time of writing, Finnrick’s partner laboratory page displayed 6,370 published Krause tests, compared with 2,408 from BTLabs and fewer than 700 from any other laboratory. On Finnrick’s own published figures, Krause therefore accounted for well over half of the results attributed to named partner laboratories on that page. Mazoyer said the imbalance resulted from the length of the relationship, affordability and Krause’s ability to accept volume. He acknowledged that relying on Krause so heavily may be a fair criticism and said bringing in additional laboratories would allow Finnrick to apply more commercial pressure around reproducibility, service and turnaround.

His more provocative answer to people who distrust Krause was that they can pay to select a different laboratory. Finnrick’s free programme chooses the laboratory; custom paid testing allows the customer to choose.

That answer is commercially straightforward but doesn’t completely resolve the public-interest concern. If Finnrick selects Krause for large numbers of free tests and uses those results in public ratings, doubts about Krause affect more than the individual submitter. They affect the database that other buyers rely on.

Why a failed identity test may not tell you what is actually inside

Another recurring source of confusion is the difference between identity confirmation and blind identification. Finnrick asks a lab whether the sample matches the substance claimed on the label and if the answer is no, the laboratory is generally instructed not to continue investigating until it identifies the unknown compound.

Mazoyer said this is deliberate. In his view, once a vial sold as retatrutide is shown not to be retatrutide, the correct consumer response is to discard it. He doesn’t want customers using Finnrick’s free programme as a way of sending an unknown substance and then deciding whether to inject it after the laboratory guesses what it may be. Finnrick may offer blind identification as a separate paid service in the future, but Mazoyer said those findings wouldn’t necessarily enter the public vendor ratings because they answer a different question.

This policy explains why a COA may report that the claimed identity wasn’t confirmed without naming the material that produced the unexpected chromatogram or mass spectrum. It doesn’t mean the laboratory is necessarily incapable of further investigation; it means that further identification was outside Finnrick’s instructions and the scope of the routine test.

How Finnrick selects and monitors laboratories

Mazoyer described four main considerations when Finnrick adds a laboratory: the credibility of its analytical process, price, capacity and turnaround time. The last of those has become particularly important after customers experienced delays extending well beyond the times initially quoted.

According to Finnrick’s announcement of 15 September 2026, it recently added Ichor Life Sciences and PharmLabs as partner laboratories. Finnrick identifies Ichor as being in Syracuse, New York. It names the second partner simply as PharmLabs, which Mazoyer described as being in California. The announcement estimates three to four weeks for Ichor and roughly one week for PharmLabs, although those are Finnrick’s targets rather than independently verified service levels.

Mazoyer said Finnrick sends several batches before using a new laboratory at scale to see whether its promised turnaround survives repeated and more difficult submissions. He said laboratories working with Finnrick know that they may be audited without notice and described an audit design in which comparable samples could be sent to several laboratories. He didn’t provide published results or say how frequently Finnrick has carried this out.

According to Mazoyer, Finnrick doesn’t currently mystery-shop laboratories. They know the samples originate through Finnrick, although the individual vial and vendor information is anonymised before analysis. Mazoyer accepts that Finnrick judges laboratory performance statistically because it’s not itself the analytical expert. Those safeguards remain Finnrick’s description of its own process, rather than an independently verified quality system. Large overlapping datasets can expose systematic differences between laboratories, but volume cannot establish analytical correctness by itself. Several laboratories could agree while sharing similar methodological limitations, assumptions or reference-material problems. Finnrick has started publishing methodology questionnaires covering quantification, sample preparation and uncertainty; that improves visibility but is not a substitute for independent method validation or proficiency testing.

What data does Finnrick hold—and what if the FDA asks for it?

Finnrick now holds an unusually broad picture of the grey peptide market. Its public database identifies hundreds of vendors, thousands of products and large numbers of test results. That naturally raises concern about whether its private records could connect individual buyers with particular vendors. Mazoyer said Finnrick is designed to retain relatively little identifying information. For a free test, he said the company generally holds an email address, an IP address and the submitted test details. Users may use burner emails, and deleting an account removes the association with the person while leaving the anonymised test result online.

Paid transactions require more. Finnrick began requesting customer names after people allegedly obtained their results and then disputed their card payments. Mazoyer said those names remain with Stripe as part of the payment record and that Finnrick doesn’t retain customer addresses. Finnrick’s privacy policy states that it collects account emails, test-request information, server logs including IP addresses and sample-submission details. It says billing is processed by Stripe, customer data is not sold, and information may be shared when required by law. Its data-deletion policy says identifying information can be removed while anonymised test results remain public.

Asked what would happen if the FDA or another authority demanded information, Mazoyer said Finnrick was well placed to resist an unlawful request. A legally valid demand would be different: “Lawful requests, I would probably need to comply.”

On cybersecurity, he avoided claiming that any database was impossible to breach. He described Finnrick as serious about security but argued that most commercially interesting vendor information is already public. Even if someone accessed unpublished records, he estimated that the additional vendor names would add only a limited amount to what can already be found openly. He made the same point when asked whether a company with Eli Lilly’s resources might seek information about sellers offering copies of retatrutide. Vendors that advertise publicly can already be found through search engines, private groups and customer accounts. In Mazoyer’s view, discovery is not the main obstacle; enforcement action after discovery is more consequential.

That response explains why he considers the risk overstated, but it didn’t provide a technical account of the database’s security. The amount of identifying customer information may be limited, yet the question of how that information is protected remains legitimate.

Expansion beyond the United States

Finnrick officially accepts testing orders from US residents. Mazoyer said the restriction is less about a technical inability to test foreign samples than the customs, payment and legal complications created when operating internationally. He would like Finnrick to expand into the United Kingdom, Australia, continental Europe and other poorly served markets, including Brazil. No timetable has been fixed. Before opening officially, he wants to establish a workable system for customs delays, fees, payments and responsibility for shipments that don’t reach Finnrick.

The need is obvious. In some countries, consumers have no practical access to professional peptide analysis and resort to crude colour tests that can only suggest the presence of peptide bonds. Those tests can’t establish identity, purity, dose or injectable safety.

Criticism and the need to communicate

Finnrick has attracted allegations that it works for regulators, pharmaceutical companies or Chinese interests. During the interview, I asked Mazoyer about a GLP-1 Forum word replacement that displays some references to the company as “Finnrisk” and has produced thread titles containing the phrase “the scammers manipulating test results for profit at Finnrisk.”

Mazoyer’s formal response was “no comment.” His longer answer was that he doesn’t understand how changing lab results would generate profit and that the forum represents only a small part of the audience Finnrick is trying to serve. He sees the company’s role as helping the much larger population buying peptides without specialist community knowledge. He nevertheless accepts that Finnrick has communicated poorly.

Asked what he would do differently if starting again, his main answer was to become louder earlier. The company concentrated on systems and operations while leaving too many decisions unexplained. That gap has helped create suspicion around unpublished tests, laboratory selection, vendor payments and access to COAs. Some criticism may be unfair, but several of the questions exist because Finnrick’s rules changed faster than its public explanations.

By the end of the interview, Mazoyer accepted an invitation to join the K-Hole Lab Chat so members and laboratory representatives could question him directly. He acknowledged the possibility that Finnrick’s presence could affect how freely laboratories speak, but agreed that direct engagement was still worth attempting.

“Arguably, I was looking for you”: the person Finnrick wants to hire

The final question concerned Finnrick’s unusually worded recruitment advert. I asked whose idea it was, why it used that style and what kind of applicant Finnrick was actually trying to attract. Mazoyer took responsibility for it. The concept and job description were his, and AI was used in producing it. The unconventional tone was deliberate: he wanted to deter conventional copywriters who might read about peptides for 15 minutes before an interview and then reproduce the language convincingly without understanding the community.

When I asked who he had in mind, he replied: “Arguably, I was looking for you. You’re the kind of person I need.” The corporate version, he said, was someone with a loud voice, or the ability to develop one, who understood the US audience. The person doesn’t need to be famous, but they do need genuine peptide experience. Mazoyer wants someone who has spent enough time inside the broad peptide world that their empathy can’t be faked. He gave the example of an ambulance driver in Kansas City who becomes the person everyone at the fire station consults about peptides. That grassroots credibility matters more to him than a conventional marketing background.

The applicant must also be comfortable with the repetitive, fast-moving and sometimes embarrassing nature of social media. Mazoyer wants someone who can edit YouTube videos, post on X, keep track of Facebook and engage in good-humoured public exchanges with outspoken figures such as Jay Campbell. He said he personally takes attacks on Finnrick to heart and is not the right person to maintain that style of banter every day. Just as important is the ability to move between communities without pretending to belong to all of them. The same person may need to speak respectfully to MAGA-aligned bodybuilders, weight-loss users, longevity enthusiasts, optimisation groups, performance athletes and people focused on recovery. Mazoyer described this as a “chameleon quality”: fluency across different cultures without faking an identity.

The position is full time and is intended to pay enough for the successful applicant to live on it. The person can technically be based in any country, although complete fluency in American social media, and probably some overlap with US working hours, would help. Finnrick hasn’t yet found the right candidate and is still hiring.

The recruitment challenge is tied to the way Finnrick itself operates. Mazoyer said the company has only four people and relies heavily on AI; he described the website and reports as being built on a large AI operation. Five years ago, he believes he might have hired 20 people and allowed some to grow into more specialised positions. AI now gives a much smaller team far more output, but it also reduces the opportunity to develop a junior employee gradually into a role this broad. The advert was therefore not merely Finnrick trying to sound provocative. It was an attempt to find a rare combination: someone already credible in peptides, fluent across several platforms, able to speak to competing subcultures and willing to become the public voice Mazoyer accepts Finnrick has so far lacked.

What the interview answered—and what it did not

The interview clarified several issues that have been poorly understood.

Finnrick has not abandoned free testing, although eligibility and publication now depend on stricter provenance checks. Basic result data remains public, while original COAs and additional tools sit behind paid access. Vendor payments don’t buy altered ratings, according to Mazoyer, but a vendor can apparently decide not to publish its initial launch submission. Finnrick collects less customer information than many assumed, although it will comply with a legally valid demand for whatever information it does hold.

Mazoyer also stands firmly behind Finnrick’s treatment of overfill. He regards dosing inaccuracy as a quality-control problem rather than a gift to the buyer, and he intends to investigate whether inaccurate filling accompanies other manufacturing failures.

Several questions remain open. The disputed Uther/Krause result still requires the specific review he promised. Finnrick hasn’t demonstrated publicly that its private database has undergone independent security testing. Its vendor programme needs clearer disclosure of which failed launch submissions remain unpublished. Most importantly, expanding beyond routine identity, purity and quantity testing will be necessary if the market is now producing vials that contain unexpected non-peptide material.

Finnrick’s scale gives it genuine value. It also gives the company considerable influence over what the public sees, which laboratories receive work and how vendors are judged. The answer isn’t to dismiss the database or accept it uncritically. It’s to keep asking how each result was obtained, why it was published, what was excluded and whether the evidence supports the grade Finnrick attached to it.